BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
hereditary angioedema
Advertisement
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
WINREVAIR Achieves Phase 2 Success in CpcPH Due to HFpEF
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
Advertisements
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
50,000 + Uses of the Syn-One Test® Mark Major Diagnostic Milestone
Scottsdale, AZ — November 6, 2025 : CND Life Sciences (CND) announced the completion of its 50,000th Syn-One Test®,...
KalVista Pharmaceuticals Highlights EKTERLY®’s Promise for Children and Strong Patient Satisfaction in HAE Treatment
Framingham, Massachusetts & Salisbury, England — November 6, 2025 : KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) presented new data at...
Intellia Completes Phase 3 Enrollment for HAE Gene Therapy
September 18, 2025 — Cambridge, Massachusetts Intellia has completed enrollment in the global Phase 3 HAELO trial of lonvoguran...
FDA Approves First RNA Therapy for Hereditary Angioedema Prophylaxis
CARLSBAD, Calif., August 21, 2025 — The U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen), the first...
Advertisement
